Publicacions en col·laboració amb investigadors/es de Copenhagen University Hospital (10)

2023

  1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  2. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  3. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    European Urology, Vol. 84, Núm. 3, pp. 321-330

2020

  1. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology

  2. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

    European Urology, Vol. 77, Núm. 2, pp. 223-250

2019

  1. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

    Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727

2018

  1. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure presented]

    European Urology

2017

  1. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial - FIRSTANA

    Journal of Clinical Oncology, Vol. 35, Núm. 28, pp. 3189-3197

2014

  1. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1263-1268

  2. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 2, pp. 76-82